Reduced expression of the SMN protein causes spinal muscular atrophy (SMA) -an inherited neurodegenerative disease characterized by multiple synaptic deficits and motor neuron loss. Here, we show that AAV9-mediated delivery of Stasimon -a gene encoding an ER-resident transmembrane protein regulated by SMN -improves motor function in a mouse model of SMA through multiple mechanisms. In proprioceptive neurons of SMA mice, Stasimon overexpression prevents the loss of afferent synapses on motor neurons and enhances sensory-motor neurotransmission. In SMA motor neurons, Stasimon suppresses the neurodegenerative process by selectively reducing phosphorylation but not upregulation of the tumor suppressor p53, both of which are converging events required to trigger neuronal death. We further show that Stasimon deficiency synergizes with SMA-related mechanisms of p53 upregulation to induce phosphorylation of p53. These findings identify Stasimon dysfunction induced by SMN deficiency as an upstream driver of cellular pathways that lead to synaptic loss and motor neuron degeneration, revealing a dual contribution of Stasimon to motor circuit pathology in SMA.
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the progressive loss of spinal motor neurons and skeletal muscle atrophy (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015) . SMA is a consequence of ubiquitous reduction in the levels of the survival motor neuron (SMN) protein due to homozygous deletion or mutation of the SMN1 gene with retention of the hypomorphic SMN2 gene (Lefebvre et al., 1995) .
SMN has a well-characterized role in the assembly of small nuclear ribonucleoproteins (snRNPs) of the splicing machinery (Meister et al., 2001; Pellizzoni et al., 2002) as well as U7 snRNP that functions in 3' end processing of histone mRNAs (Pillai et al., 2003; Tisdale et al., 2013) . SMN has also been implicated in other aspects of RNA regulation including mRNA transport (DonlinAsp et al., 2017) . Consistent with its central role in RNA processing (Donlin-Asp et al., 2016; Li et al., 2014) , SMN deficiency has been shown to induce widespread splicing dysregulation and transcriptome alterations in a variety of in vivo models (Bäumer et al., 2009; Doktor et al., 2017; Jangi et al., 2017; Zhang et al., 2008 Zhang et al., , 2013 . The identification of downstream RNA targets of SMN deficiency that directly contribute to SMA pathology is of critical importance for elucidating disease mechanisms and revealing SMN-independent therapeutic approaches. To date, however, this has proven to be challenging due to the diversity of RNA pathways controlled by SMN and the complexity of SMA pathology in mouse models that more closely resemble the most severe form of the human disease.
Motor neurons are the cell type most severely affected by SMN deficiency, and their degeneration is a hallmark of SMA pathology (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015) . Importantly, selective genetic restoration of SMN in motor neurons of SMA mice has demonstrated that neuronal death is a cell autonomous process (Fletcher et al., 2017; Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015) . We previously demonstrated that activation of the tumor suppressor p53 is a key driver of motor neuron degeneration in the SMND7 mouse model of SMA . We also showed that selectivity is established through the convergence of distinct mechanisms of p53 regulation including stabilization and phosphorylation of its N-terminal transcription-activation domain (TAD) , which only occur in the pool of vulnerable SMA motor neurons destined to die. Recently, we demonstrated that p53 upregulation results from dysregulated alternative splicing of Mdm2 and Mdm4 -the two main inhibitors of p53's stability and function (Toledo and Wahl, 2006; Vousden and Prives, 2009 ) -due to reduced snRNP levels in SMA motor neurons (Van Alstyne et al., 2018a) , thereby directly linking neurodegeneration to specific splicing changes induced by SMN deficiency. However, the converging mechanism(s) responsible for selective phosphorylation of the TAD of p53 required for degeneration of SMA motor neurons is unknown.
Characterization of SMA pathogenesis has identified multiple synaptic deficits in the motor circuit beyond motor neuron death that include dysfunction and loss of neuromuscular junctions (NMJ) as well as central proprioceptive sensory synapses onto motor neurons (Shorrock et al., 2019; Van Alstyne and Pellizzoni, 2016) , which likely exert compounding effects on neuromuscular function. Studies in mouse models indicated that NMJ denervation occurs as a consequence of intrinsic effects of SMN deficiency in SMA motor neurons rather than skeletal muscle (Fletcher et al., 2017; Gavrilina et al., 2008; Iyer et al., 2015; Martinez et al., 2012) and that the pathogenic processes underlying NMJ denervation and death of motor neurons might be distinct (Kim et al., 2017; Van Alstyne et al., 2018a) . The dysfunction and loss of proprioceptive synapses on somata and dendrites of SMA motor neurons is an early pathogenic event in SMA mice (Mentis et al., 2011) , which is caused by the effects of SMN deficiency within proprioceptive neurons (Fletcher et al., 2017) . The resulting reduction of excitatory drive from proprioceptive synapses induces hyperexcitability and reduces the firing of motor neurons contributing to impaired muscle contraction in SMA mice (Fletcher et al., 2017) . Moreover, the deafferentation and dysfunction of motor neurons are mechanistically uncoupled from motor neuron death (Fletcher et al., 2017; Simon et al., 2016) . However, while multiple insults to the synaptic integrity of sensory-motor circuits originate from defects in distinct neurons that coalesce to cause SMA pathology, the underlying SMN-dependent mechanisms are poorly understood.
This work aimed to address the outstanding questions described above by investigating the potential contribution of Stasimon dysfunction to SMA pathology in a mouse model of the disease. We previously identified Stasimon (also known as Tmem41b) as an evolutionarily conserved, U12 intron-containing gene regulated by SMN that is required for proper synaptic transmission in the motor circuit of Drosophila larvae and motor axon outgrowth in zebrafish (Lotti et al., 2012) . Importantly, Stasimon contributes to motor circuit deficits in Drosophila and zebrafish models of SMA as its overexpression suppresses specific neuronal phenotypes induced by SMN deficiency in these model organisms (Lotti et al., 2012) . Furthermore, we and others have found that SMN deficiency disrupts U12 splicing (Boulisfane et al., 2011; Doktor et al., 2017; Jangi et al., 2017; Lotti et al., 2012) , and both misprocessing and reduced expression of Stasimon mRNA was found in disease-relevant motor circuit neurons of SMA mice (Lotti et al., 2012) . Recent studies have also shown that Stasimon is a transmembrane protein localized to the ER that is essential for mouse embryonic development (Van Alstyne et al., 2018b) and involved in autophagy (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 2019) . However, Stasimon's normal requirement in the mammalian motor circuit and a direct involvement in pathogenesis of SMA mouse models have not been established.
Here, we investigated the effects of Stasimon restoration in the SMND7 mouse model of SMA by means of adeno-associated virus serotype 9 (AAV9)-mediated gene delivery. We found that overexpression of Stasimon rescues the loss of proprioceptive synapses on motor neurons, improves synaptic transmission, and suppresses motor neuron degeneration. Mechanistically, we demonstrate that the loss of Stasimon is sufficient to induce p53 phosphorylation, a key event underlying the selective degeneration of SMA motor neurons . Together, these results establish Stasimon's direct involvement in distinct pathogenic cascades induced by SMN deficiency in proprioceptive neurons and motor neurons, revealing a dual contribution by Stasimon to sensory-motor circuit dysfunction in a mouse model of SMA.
Results

AAV9-mediated Stasimon gene delivery improves motor function in SMA mice.
We sought to investigate the effects of increased expression of human Stasimon (abbreviated as STAS) on the phenotype of SMNΔ7 SMA mice by intracerebroventricular (ICV) injection of self-complementary AAV9 vectors at P0, an established method to study SMA disease mechanisms in vivo (Passini et al., 2010; Simon et al., 2017; Van Alstyne et al., 2018a) . RT-qPCR analysis confirmed that injection of AAV9-STAS as well as AAV9-GFP and AAV9-SMN, which were used as negative and positive controls, respectively, resulted in robust expression of the corresponding mRNAs in the spinal cord of SMA mice at P11 ( Figure 1A ). AAV9-STAS did not increase full-length SMN2 mRNA or SMN protein levels in the spinal cords of SMA mice ( Figure   1A and 1B). To rule out any potential indirect effects of AAV9-STAS on SMN function, we also looked at representative downstream targets of SMN-regulated RNA pathways. AAV9-STAS did not correct aberrant U12 splicing of endogenous Stasimon pre-mRNA (Lotti et al., 2012) or other RNA processing events such as U7-dependent histone H1c 3ʹ end misprocessing (Tisdale et al., 2013) , p53-dependent induction of Cdkn1a mRNA and reduced Chodl mRNA expression (Bäumer et al., 2009; Zhang et al., 2008) in the spinal cord of SMA mice at P11 ( Figure   1C ). In contrast, all of these SMN-dependent events were robustly corrected by AAV9-SMN as expected ( Figure 1C ). Consistent with Stasimon being a downstream mRNA target of U12 splicing dysfunction induced by SMN deficiency (Lotti et al., 2012 ), these results demonstrate that AAV9-STAS does not enhance SMN expression or function.
We next investigated the effects of AAV9-STAS on the disease phenotype of SMA mice, which exhibit reduced weight, shortened life span and impaired motor behavior (Le et al., 2005) .
WT mice injected with AAV9-STAS showed no phenotypic abnormalities relative to uninjected WT littermates ( Figure 1D-F) , indicating no toxic effects of Stasimon overexpression in vivo.
Furthermore, AAV9-SMN corrected all behavioral parameters and robustly extended survival in SMA as described previously (Foust et al., 2010; Passini et al., 2010) . Remarkably, while AAV9-STAS had no effects on weight gain and survival, it improved motor behavior of SMA mice assessed by righting time ( Figure 1D-F) . Thus, Stasimon contributes to the motor phenotype of SMA mice, and the functional improvement elicited by AAV9-STAS occurs through SMNindependent mechanisms.
AAV9-STAS rescues the loss of proprioceptive synapses on SMA motor neurons.
To identify morphological improvements underlying the motor benefit of Stasimon restoration in SMA mice, we focused on synaptic connectivity of sensory-motor circuits controlling disease-relevant axial muscles. First, we analyzed the number of proprioceptive synapses onto motor neurons in the L1 lumbar spinal segment, which are strongly reduced in SMA mice (Mentis et al., 2011) . To do so, we used immunohistochemistry with antibodies against the vesicular glutamate transporter 1 (VGluT1) to label proprioceptive synapses, and choline acetyltransferase To examine the selectivity of Stasimon's effects on synaptic loss, we investigated neuromuscular junction (NMJ) innervation of the quadratus lumborum (QL), a disease-relevant axial muscle innervated by vulnerable L1-L3 motor neurons that is severely denervated in SMA mice (Fletcher et al., 2017; Simon et al., 2017; Van Alstyne et al., 2018a) . To do so, we used antibodies against neurofilament (NF-M) and synaptophysin (SYP) as presynaptic markers and fluorescently-labeled α-bungarotoxin (BTX) to label the acetylcholine receptor clusters on muscle fibers. At P11, NMJs of the QL in SMA animals injected with AAV9-GFP display ~40% denervation in contrast to a fully innervated QL in WT mice (Figure 2B and 2E) . Moreover, while AAV9-SMN injection restored NMJ innervation of the QL to near normal levels, AAV9-STAS did not have any beneficial effect on NMJ denervation in SMA mice (Figure 2B and 2E) .
Taken together, these results reveal that Stasimon selectively restores the number of proprioceptive synapses in the sensory-motor circuit of SMA mice.
Stasimon acts in proprioceptive neurons to improve sensory-motor synaptic transmission in SMA mice.
We sought to determine whether restoration of proprioceptive synapses on SMA motor neurons by AAV9-STAS resulted in functional improvement of sensory-motor neurotransmission, which is severely disrupted in SMA mice (Fletcher et al., 2017; Mentis et al., 2011) . To do so, we used the spinal cord ex vivo preparation and determined the amplitude of the sensory-motor monosynaptic reflex in the L1 spinal segment by simultaneous stimulation of the L1 dorsal root and recording from the ventral root of WT and SMA mice at P11 (Mentis et al., 2011) . The amplitude of the monosynaptic reflex was reduced by ~95% in SMA mice injected with AAV9-GFP and robustly enhanced upon SMN restoration with AAV9-SMN ( Figure 3A and 3B). When we analyzed SMA mice injected with AAV9-STAS, we identified two distinct physiological responses in approximately equal proportions: a group of AAV9-STAS mice that exhibited a robust improvement of the monosynaptic reflex comparable to that of AAV9-SMN-injected SMA mice ( Figure 3A and 3B), and another group that did not show increased response relative to AAV9-GFP treated SMA mice ( Figure S1A ). There were no significant differences between the two groups of SMA mice treated with AAV9-STAS in their body weight ( Figure S1B ), the levels of viral-mediated STAS mRNA overexpression in the spinal cord ( Figure S1C ), or the number of proprioceptive synapses on SMA motor neurons (aggregated data are shown in Figure 2 ) that could account for this observation. However, there was correlation with the motor performance of these SMA mice. We found that AAV9-STAS (R, righting) treated SMA mice that were able to right at the time of the assay ( Figure S1D ) had robust spinal reflex amplitudes ( Figure 3A and 3B and Figure S1A ), while AAV9-STAS (NR, non-righting) SMA mice with poor righting ability ( Figure   S1D ) had small amplitudes ( Figure S1A ). Moreover, the levels of exon 7 containing, full-length SMN2 mRNA were higher in the spinal cord of AAV9-STAS (R) relative to AAV9-STAS (NR) SMA mice ( Figure S1E ). A marked reduction of SMN2 exon 7 splicing ensues at late symptomatic stages in SMA mice due to hypoxia and malnourishment, which exacerbate disease progression (Bebee et al., 2012; Sahashi et al., 2012) . Thus, the observed differences in the electrophysiological responses of AAV9-STAS treated mice might reflect a degree of heterogeneity in the underlying severity of the SMA phenotype. Nevertheless, these experiments suggest that AAV9-STAS-mediated restoration of proprioceptive synapses can result in functional improvement of sensory-motor neurotransmission that correlates with enhanced motor function in SMA mice.
We next investigated NMJ function by stimulating motor axons in the L1 ventral root and recording the resultant compound muscle action potential (CMAP) in the QL muscle at P11. The CMAP of SMA mice injected with AAV9-GFP is strongly reduced compared to WT mice and significantly improved by AAV9-SMN injection ( Figure 3C and 3D). AAV9-STAS-injected SMA mice did not show any improvement in the CMAP ( Figure 3C and 3D), which was the case irrespective of their motor behavior or spinal reflex amplitudes at the time of the assay ( Figure   S1F ), and consistent with the lack of effects on NMJ innervation (Figure 2B and 2E) . Thus, the effects of Stasimon are selective for proprioceptive sensory synapses in SMA mice.
To dissect further the Stasimon-dependent functional improvement of the sensory motor circuit, we first determined the cellular contribution of motor neurons and proprioceptive synapses to the amplitude of the monosynaptic reflex in SMA mice. To do so, we restored SMN selectively in either proprioceptive neurons (SMA+SMN (PV-Cre)) or motor neurons (SMA+SMN (ChATCre)) of SMA mice using a previously characterized conditional allele for Cre-dependent SMN restoration (Lutz et al., 2011) . This approach rescues the number and function of proprioceptive neurons in SMA+SMN (PV-Cre) mice and motor neuron survival in SMA+SMN (ChAT-Cre), respectively (Fletcher et al., 2017) . We found that motor neurons and proprioceptive neurons equally contribute to the reduction in the amplitude of the monosynaptic reflex of SMA mice ( Figure S1G and S1H). To determine the reliability of neurotransmission of proprioceptive synapses irrespective of the number of motor neurons present, we performed repetitive stimulation of the sensory dorsal root L1 with simultaneous recording of the ventral root at high frequency (10 Hz) and compared the monosynaptic amplitude of the 1 st with the 5 th stimulus. We found a decrease of the monosynaptic amplitude of ~40% in WT and ~70% in SMA mice ( Figure   S1I and S1J), revealing higher synaptic depression in SMA mice likely due to impaired neurotransmission. While selective SMN restoration in motor neurons of SMA+SMN (ChAT-Cre) mice did not have any benefit, SMN expression in proprioceptive neurons of SMA+SMN (PV-Cre) mice reduced the synaptic depression of the monosynaptic reflex to WT levels, confirming that this experimental approach distinguishes the presynaptic contribution of proprioceptive neurotransmission in SMA ( Figure S1I and S1J). Importantly, SMA mice injected with AAV9-STAS showed correction of synaptic depression to levels comparable to WT and AAV9-SMN treated SMA mice ( Figure 3E and 3F). Collectively, these results indicate that AAV9-STAS ameliorates SMN-dependent sensory-motor circuit deficits by improving synaptic transmission in proprioceptive neurons of SMA mice.
Stasimon contributes to motor neuron degeneration in SMA mice.
Loss of motor neurons is a hallmark of SMA pathology (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015) and we investigated whether Stasimon was implicated in this neurodegenerative process. To do so, we performed immunohistochemistry experiments and visualized motor neurons in the L1 and L5 spinal segments with antibodies against ChAT ( Figure   4A and 4C). SMA mice injected with AAV-GFP displayed a loss of vulnerable L1 and L5 medial motor column (MMC) motor neurons at P11 ( Figure 4B and 4D). Importantly, AAV9-STAS corrected this loss of SMA motor neurons with an efficacy similar to AAV9-SMN ( Figure 4B and 4D). We recently showed that motor neuron death is caused by distinct, converging mechanisms of p53 activation in the SMND7 mouse model Van Alstyne et al., 2018a) . To investigate whether Stasimon suppresses motor neuron death through the p53 pathway, we first immunostained against p53 and found no effects of AAV9-STAS on the number of p53+ L5 MMC motor neurons relative to AAV9-GFP treated SMA mice ( Figure 5A and 5B Stasimon deficiency is sufficient to induce p53 S18 phosphorylation.
Recent studies have shown that Stasimon is required for autophagy in cultured mammalian cells (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 2019) . Therefore, we sought to investigate the possible involvement of Stasimon-dependent autophagy dysregulation in SMA pathogenesis. First, we established a stable NIH3T3 cell line (NIH3T3-StasRNAi) in which Stasimon mRNA levels are reduced to ~10% of normal as monitored by RT-qPCR ( Figure S2A ).
We then analyzed by Western blot the levels of the autophagy proteins p62 and LC3 in WT and StasRNAi NIH3T3 cells under basal conditions and following autophagy induction with serum starvation or inhibition by Bafilomycin A1 treatment ( Figure S2B ). We found that the levels of p62
and lipidated LC3 (LC3-II) were moderately increased in Stasimon-deficient relative to WT cells, consistent with dysregulation of autophagy (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 2019) . However, Western blot analysis showed no changes in the levels of both p62 and LC3 in spinal cords from WT and SMA mice at P11 ( Figure S2C ). Additionally, we performed immunohistochemistry experiments to investigate p62 expression in L1 motor neurons and proprioceptive neurons from L1 dorsal root ganglia (DRGs) of WT and SMA mice at P11 ( Figure   S2D and S2E), but did not find any major difference in the levels and localization of p62 induced by SMN deficiency in these disease-relevant neurons in vivo. These results suggest that autophagy dysregulation is unlikely to underlie the Stasimon-dependent deficits in SMA motor circuit.
Next, we sought to determine whether loss of Stasimon is sufficient to induce p53 S18 phosphorylation as suggested by the reduction of p-p53 S18 in SMA motor neurons described above. We have previously shown that upregulation but not N-terminal phosphorylation of p53 in Based on our findings and earlier genetic studies in SMA mice, it is plausible to draw some conclusions with regard to the spatial contribution of Stasimon to motor circuit pathology ( Figure   7 ). On one hand, selective restoration of SMN in motor neurons indicated that induction of cell death is cell autonomous (Fletcher et al., 2017; Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015) , suggesting that the effects of AAV9-STAS on SMA motor neuron survival are mediated by Stasimon restoration in these cells. On the other hand, deafferentation is caused by SMN deficiency in proprioceptive neurons (Fletcher et al., 2017) Recent studies have shown that Stasimon is an ER-resident six-transmembrane pass protein that is essential for mouse embryonic development (Van Alstyne et al., 2018b) and functions in autophagy (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 2019) . However, we found no evidence for overt autophagy dysregulation in motor circuit neurons of SMA mice.
Furthermore, Stasimon is enriched at ER-mitochondrial contact sites (Van Alstyne et al., 2018b) , which are implicated in a variety of biological processes beyond autophagy that are important for neuronal physiology and disease (Paillusson et al., 2016) . Elucidation of the downstream molecular mechanisms underlying dysfunction and loss of proprioceptive synapses in SMA will require greater knowledge of the full breadth of Stasimon functions. It will also need to integrate previous, seemingly unrelated findings implicating dysregulation of endocytosis (Ackermann et al., 2013; Hosseinibarkooie et al., 2016; Janzen et al., 2018; Riessland et al., 2017 ) and UBA1/GARS-dependent pathways (Shorrock et al., 2018) in the loss of SMA proprioceptive synapses into a coherent model.
The observation that Stasimon restoration suppresses motor neuron degeneration was unexpected, and we sought a mechanistic explanation in the context of the current understanding of the motor neuron death pathway. Based on previous studies in the SMND7 mouse model of SMA , we have proposed a model in which selective degeneration of vulnerable SMA motor neurons requires the convergence of p53 stabilization with one or more additional events, which include post-translational modifications of p53 such as phosphorylation of its N-terminal TAD that specifically direct the p53 response towards degeneration (Figure 7) .
Recently, we demonstrated that dysregulation of Mdm2 and Mdm4 alternative splicing induced by SMN-dependent snRNP dysfunction underlies the upregulation of p53 in SMA motor neurons (Van Alstyne et al., 2018a) . We also showed that these events are necessary but not sufficient to induce motor neuron death in vivo (Van Alstyne et al., 2018a) , leaving open the question as to which SMN function(s) and downstream targets are involved in the other branch of the p53-dependent motor neuron death pathway. Our findings that AAV9-STAS reduces phosphorylation of p53 S18 and rescues survival in SMA motor neurons in vivo together with the observation that Stasimon deficiency is sufficient to induce p53 S18 phosphorylation in vitro fill this knowledge gap and place Stasimon dysfunction as an upstream driver of the neurodegenerative cascade. Since degeneration of SMA motor neurons requires phosphorylation of p53 at multiple residues beyond S18 , Stasimon likely triggers some of these additional p53 modifications required for neurodegeneration, but the lack of specific reagents prevents their identification at this time. Future studies will also be needed to determine whether Stasimon deficiency is sufficient to drive SMA motor neuron death when converging with Mdm2-and Mdm4-mediated p53 upregulation.
In summary, our work identifies Stasimon as a key determinant of defective synaptic connectivity and function in the SMA sensory-motor circuit as well as an upstream trigger of a signaling cascade(s) that feeds into p53 and the motor neuron cell death pathway. SMN deficiency has previously been linked to the activation of several kinases implicated in the degeneration of SMA motor neurons (Genabai et al., 2015; Kannan et al., 2018; Miller et al., 2015; Ng et al., 2015) and known to phosphorylate p53 (Toledo and Wahl, 2006; Vousden and Prives, 2009 ). Identification of the Stasimon-dependent signal transduction pathways and kinase(s) that drive p53 phosphorylation and motor neuron death in SMA might reveal viable targets for the development of neuroprotective agents for SMA therapy. Thus, further characterization of Stasimon biology will not only provide critical insight into the mechanisms underlying normal development and disease of the motor circuit but may also yield novel targets for developing SMN-independent SMA therapeutics.
Material and Methods
DNA cloning and viral production
For AAV9 production, DNA fragments corresponding to the open reading frames of GFP, human SMN (NM_000344), and human STAS (NM_015012) were generated by PCR using plasmid templates obtained from OriGene and cloned downstream of the CMV enhancer and chicken beta-actin (CB) hybrid promoter in the dsAAV-CB plasmid (a gift from Brian Kaspar)
harboring AAV2 ITRs for the production of self-complementary AAV9 (Foust et al., 2010) . The corresponding AAV9 vectors packaged into serotype-9 capsid were custom produced by Vector BioLabs using triple plasmid transfection of HEK293 cells and purification by two rounds of CsCl gradient centrifugation. Titer and purity of each AAV9 preparation were confirmed in-house by qPCR (see Table S1 for the sequence of primers) and silver staining, respectively. 
Cell lines and treatments
The NIH3T3-StasRNAi cell line was generated by transduction of NIH3T3 cells with pLenti.pur/StasRNAi, followed by antibiotic selection with 5 μg/ml Puromycin (Sigma) and cloning by limiting dilution as described before (Lotti et al., 2012; Ruggiu et al., 2012 paraformaldehyde (PFA) in PBS for 30 minutes at room temperature, and permeabilized with 0.5% Triton X-100-PBS for 5 minutes on ice. Blocking and incubation with both primary and secondary antibodies were performed using 3% bovine serum albumin (BSA) in PBS for 1 hour at room temperature. Images were collected with an SP5 Leica confocal microscope. genotyping was performed as described previously (Fletcher et al., 2017) . See Table S1 for the sequence of all primers. For AAV9 gene delivery, P0 mice were anesthetized by isoflurane inhalation and injected in the right lateral ventricle of the brain with ~1x 10 11 genome copies of AAV9 vectors in a PBS solution containing a vital dye (Fast Green; Sigma-Aldrich). Approximately equal proportions of mice of both sexes were used in all experiments, and aggregated data are presented because gender-specific differences were not found.
Animal procedures and behavioral analysis
For behavioral analysis, mice from all experimental groups were monitored daily, weighed, and three righting reflex tests were timed and averaged as described previously (Mentis et al., 2011) . Mice with 25% weight loss and an inability to right were euthanized with carbon dioxide to comply with IACUC guidelines. Righting time was defined as the time for the pup to turn over on its limbs after being placed on its back. The cut-off test time for the righting reflex was 60 seconds to comply with IACUC guidelines.
Immunohistochemistry
For immunostaining of the spinal cord, mice were sacrificed at P11, the spinal cord was removed natively and post-fixed in 4% PFA overnight at 4°C. On the following day, the spinal cords were briefly washed with PBS, subsequently embedded in warm 5% Agar and serial transverse sections (75 μm) were cut on a Leica VT1000S vibratome. The sections were blocked with 10% normal donkey serum in 0.01 M PBS with 0.3% Triton X-100 (PBS-T; pH 7.4) for 1.5 hours and incubated overnight at room temperature in different combinations of the primary antibodies (see Table S2 for antibody details). The following day, after six 10-minute washes with PBS, secondary antibody incubations were performed for 3 hours with the appropriate speciesspecific antiserum coupled to FITC, Cy3 or Cy5 (Jackson labs) diluted at 1:250 in PBS-T. After secondary antibody incubations, the sections were washed six times for 10 minutes in PBS and mounted on slides and cover-slipped with an anti-fading solution made of Glycerol:PBS (3:7).
For immunostaining of NMJs, mice were sacrificed at P11 and the QL muscle was dissected and immediately fixed with 4% PFA for 20 minutes. After fixation, single muscle fibers were teased and washed five times in PBS for 10 minutes each followed by staining of the postsynaptic part of the NMJ with α-bungarotoxin coupled to Alexa Fluor 555 in PBS for 20 minutes. Subsequently, the muscle fibers were washed five times in PBS for 10 minutes and blocked with 10% donkey serum in PBS-T for 1 hour. Anti-Neurofilament-M and antiSynaptophysin 1 antibodies to immunolabel the presynaptic part of the NMJ were applied in blocking solution overnight at 4°C (see Table S2 for antibody details). The muscle fibers were then washed 3 times for 10 minutes in PBS. Secondary antibodies were applied for 1 hour in blocking solution at room temperature. Finally, the muscle fibers were washed 3 times in PBS for 10 minutes and mounted with Vectashield (Vector laboratories, CA) (Simon et al., 2010) .
Confocal microscopy
Confocal microscopy was performed using either SP5 or SP8 (Leica) confocal microscopes as described previously Van Alstyne et al., 2018a) . Sections were scanned using a 20x or 40x objective. Motor neurons were counted off-line from z-stack images (collected at 3μm intervals in the z axis) from eleven sections of the selected L1 and L5
spinal segments as we previously described Van Alstyne et al., 2018a) . Only
ChAT+ motor neurons that contained the nucleus were counted to avoid double counting from adjoining sections. Quantitative analysis of VGluT1 immunoreactive synaptic densities on motor neurons was performed on image stacks of optical sections scanned using a 40x oil (N. A. 1.25) objective throughout the whole section thickness at 0.4μm z-steps to include the whole cell body and dendrites of ChAT+ motor neurons. The number of VGluT1+ synapses were counted over the entire surface of the motor neuron soma as well as on primary dendrites up to a distance of 100 µm from the soma using Leica LASAF software as previously described (Mentis et al., 2011) .
For the analysis of muscle innervation, at least 200 randomly selected NMJs per muscle sample were quantified for each biological replicate. Only BTX+ endplates that lacked any pre-synaptic coverage by both synaptophysin and NF-M were scored as fully denervated.
Electrophysiology
To record the monosynaptic reflex, we conducted the experiment as previously described . The animals were decapitated at P11, the spinal cords dissected and removed under cold (~12°C) artificial cerebrospinal fluid (aCSF) containing 128.35 mM NaCl, 4 mM KCl, 0.58 mM NaH2PO4.H20, 21 mM NaHCO3, 30 mM D-Glucose, 1.5 mM CaCl2.H20, and 1 mM To functionally assess NMJs of the QL muscle at P11, we applied the same technique as described previously (Fletcher et al., 2017) . Motor neurons axons in the ventral root L1
supplying the QL muscle were stimulated by drawing the ventral root into a suction electrode, having removed the spinal cord, and the CMAP was recorded from the muscle using a concentric bipolar electrode. L1 motor neuron axons were stimulated with five stimuli at 0.1Hz.
The maximum CMAP amplitude (baseline-to-peak) was measured from five averages.
RNA and protein analysis
For RNA analysis from NIH3T3 cells and mouse tissue, total RNA purification and RTqPCR experiments were carried out as previously described (Lotti et al., 2012; Van Alstyne et al., 2018a) . The primers used are listed in Table S1 . For protein analysis, NIH3T3 cells and mouse tissues were homogenized directly in SDS-PAGE sample buffer and electrophoresed on a 12% SDS-PAGE gel followed by Western blotting as previously described (Ruggiu et al., 2012) . The antibodies used are listed in Table S2 .
Statistics
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